SCHEDULE 13G/A: L1 Capital Global Opportunities Master Fund Significantly Reduces Stake in Aptevo Therapeutics

L1 Capital Global Opportunities Master Fund, Ltd. has amended its Schedule 13G filing, reporting a substantial reduction in its beneficial ownership of Aptevo Therapeutics Inc. common stock.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd. filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in Aptevo Therapeutics Inc. common stock.
• The fund now beneficially owns 20,000 Warrants of Aptevo Therapeutics Inc., representing 0.70% of the class.
• This updated ownership is based on 2,864,156 Common Stock outstanding immediately after an offering, assuming no exercise of pre-funded or common warrants, as per the Issuer's Prospectus filed on June 20, 2025.
• The previous Schedule 13G, filed on April 25, 2025, covered 421,000 shares of Common Stock purchased on April 21, 2025.
• L1 Capital Global Opportunities Master Fund, Ltd. holds sole voting power and sole dispositive power over the 20,000 Warrants.
• David Feldman and Joel Arber are identified as Directors of L1 Capital Global Opportunities Master Fund, Ltd., and may be deemed to beneficially own the securities, though they disclaim beneficial ownership for other purposes.

Sentiment

Score: 2

Explanation: The sentiment is negative due to the substantial reduction in beneficial ownership by a significant institutional investor, which could imply a loss of confidence or a strategic divestment.

Negatives

• L1 Capital Global Opportunities Master Fund, Ltd. has significantly reduced its reported beneficial ownership in Aptevo Therapeutics Inc. from 421,000 shares of Common Stock to 20,000 Warrants.
• The current beneficial ownership of 0.70% is a very small stake, indicating a lack of significant conviction or a divestment strategy by the fund.

Risks

• A significant reduction in institutional ownership by a fund like L1 Capital Global Opportunities Master Fund, Ltd. could signal a loss of confidence in Aptevo Therapeutics Inc.'s future prospects, potentially leading to negative market sentiment.
• The reduction in stake might indicate that the fund has re-evaluated its investment thesis for Aptevo Therapeutics Inc., which could be a concern for other investors.

Future Outlook

No forward-looking statements or guidance from Aptevo Therapeutics Inc. are provided in this beneficial ownership filing.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a change in an institutional investor's position within the biotechnology and pharmaceutical sector. Such changes can sometimes signal shifts in investor confidence or portfolio rebalancing within the industry, particularly for smaller-cap companies like Aptevo Therapeutics Inc.

Stakeholder Impact

• Shareholders may perceive the significant reduction in institutional ownership as a negative signal, potentially impacting investor confidence and the company's stock price.
• The reduced stake by an institutional investor could make it more challenging for Aptevo Therapeutics Inc. to attract new institutional capital in the future.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, L1 Capital Global Opportunities Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing